8-K: Network-1 Reports Q2 2026 Results: Increased Losses, Zero Revenue

Network-1 Technologies, Inc. announced its second quarter 2026 financial results, reporting no revenue for the quarter and a net loss of $655,000, with operating expenses rising significantly.

Summary

• Network-1 Technologies reported no revenue for the three months ended June 30, 2026, and $0 for the six months ended June 30, 2026, compared to $150,000 in the prior year's six-month period.
• Operating expenses increased to $1,013,000 for Q2 2026 from $720,000 in Q2 2025, and for the six-month period, expenses rose to $2,428,000 from $1,515,000.
• The company recorded a net loss of $655,000 ($0.03 per share) for Q2 2026, an increase from a net loss of $463,000 ($0.02 per share) in Q2 2025.
• For the six months ended June 30, 2026, the net loss was $1,166,000 ($0.05 per share), compared to $826,000 ($0.04 per share) in the same period of 2025.
• A gain of $1,052,000 was recognized in Q1 2026 from the remeasurement of its investment in ILiAD Biotechnologies, Inc. following ILiAD's financing round.
• As of June 30, 2026, Network-1 had $33,752,000 in cash, cash equivalents, and marketable securities, with working capital of $33,179,000.
• The company continues to pursue four pending patent litigations and has scheduled trial dates for cases against Samsung (June 7, 2027) and Google/YouTube (December 7, 2026).

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to increased operating expenses, a widening net loss, and zero revenue in the current quarter, despite a one-time gain from an investment.

Positives

• The company holds $33,752,000 in cash, cash equivalents, and marketable securities as of June 30, 2026, which management believes is sufficient for foreseeable operations.
• A gain of $1,052,000 was recognized in the first quarter of 2026 related to the investment in ILiAD Biotechnologies, Inc.
• Network-1 returned over $45,800,000 to shareholders through dividends and share repurchases from 2010 through June 30, 2026.
• The company declared and paid a semiannual cash dividend of $0.05 per share in March 2026, consistent with its policy.

Negatives

• Revenue was $0 for the three months ended June 30, 2026, and $0 for the six months ended June 30, 2026.
• Operating expenses increased by 40.7% to $1,013,000 in Q2 2026 compared to $720,000 in Q2 2025.
• The net loss for Q2 2026 was $655,000, a 41.5% increase from the $463,000 net loss in Q2 2025.
• For the six-month period, the net loss increased by 41.3% to $1,166,000 from $826,000 in the prior year.
• The increases in operating expenses and net loss are primarily attributed to higher litigation-related professional fees and costs.

Risks

• Uncertainty regarding revenue from licensing intellectual property.
• Uncertainty as to the outcome of pending litigation involving its M2M/IoT, HFT, and Cox patent portfolios.
• Ability to successfully execute its strategy to acquire or invest in high-quality patents with significant licensing opportunities.
• Ability to achieve revenue and profits from its M2M/IoT, HFT, Smart Home, and Cox patent portfolios.
• Successful outcome on its investment in ILiAD Biotechnologies, Inc. or other intellectual property acquired or financed.
• Ability to enter into additional license agreements.
• Uncertainty as to whether cash dividends will continue to be paid.
• Risk of being classified as a Personal Holding Company in the future, potentially requiring a special cash dividend.

Future Outlook

Management believes the company has sufficient liquidity to fund operations for the foreseeable future. The company continues to pursue its patent litigations and aims to monetize its patent portfolios.

Management Comments

• "Network-1 continues to pursue four pending patent litigations involving its M2M/IoT, HFT and Cox patent portfolios."
• "Management believes that based on Network-1s current cash position, it has sufficient liquidity to fund operations for the foreseeable future."
• "Network-1s dividend policy consists of semiannual cash dividends of $0.05 per share ($0.10 per share annually), historically paid in March and September."
• "Network-1s strategy is to focus on acquiring and investing in high quality patents which management believes have the potential to generate significant licensing opportunities."

Industry Context

StockSavvy.ai notes that Network-1 operates in the intellectual property monetization sector, which is characterized by significant litigation costs and the potential for high returns from successful patent enforcement or licensing. The increased litigation expenses reflect the company's active pursuit of its patent rights, a common strategy in this industry.

Legal Proceedings

• Patent litigation against Samsung Electronics Co., LTD and Samsung Electronics America, Inc. for infringement of six patents within Network-1's M2M/IoT Patent Portfolio, with a trial date scheduled for June 7, 2027.
• Litigation against Google and YouTube involving the Cox patent portfolio, where the U.S. Court of Appeals for the Federal Circuit overturned a judgment of non-infringement, remanding the matter for further proceedings, with a trial date scheduled for December 7, 2026.

Stakeholder Impact

• Shareholders: Increased net loss and zero revenue may negatively impact share price. Continued dividend payments and share repurchases are positive.
• Creditors: Sufficient liquidity and working capital suggest no immediate impact on creditors.
• Employees: Increased litigation costs may indirectly impact resources available for employee initiatives.
• Suppliers: Increased operating expenses may lead to higher payments to professional service providers.

Next Steps

• Continue to pursue four pending patent litigations.
• Monetize M2M/IoT, HFT, Cox, and Smart Home patent portfolios.
• Focus on acquiring and investing in high-quality patents with significant licensing opportunities.
• Proceed with scheduled trial dates for litigation against Samsung and Google/YouTube.

Key Dates

Recommendation

The company's zero revenue, increasing losses, and high litigation expenses present significant concerns. However, its substantial cash reserves, ongoing patent monetization strategy, and past successes in IP licensing provide some underlying value. The upcoming trial dates are critical catalysts. A 'hold' recommendation reflects the balance between significant risks and potential upside from successful litigation and IP monetization.

Keywords

intellectual property, patent litigation, licensing, M2M/IoT, HFT, Cox patent portfolio, ILiAD Biotechnologies, eSIM